NASDAQ:ARPO
Delisted
Aerpio Pharmaceuticals Inc. Stock News
$13.14
-0.370 (-2.74%)
At Close: Aug 17, 2022
Leap Therapeutics (LPTX) Soars: Stock Adds 8.3% in Session
12:32pm, Monday, 15'th Jun 2020
Leap Therapeutics (LPTX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Is Aerpio Pharmaceuticals (ARPO) Stock Outpacing Its Medical Peers This Year?
03:30pm, Friday, 12'th Jun 2020
Is (ARPO) Outperforming Other Medical Stocks This Year?
Gubernur: Pangandaran contoh penerapan normal baru sektor pariwisata
08:50am, Thursday, 11'th Jun 2020
Gubernur Jawa Barat Ridwan Kamil (Kang Emil) mengapresiasi penerapan adaptasi kebiasaan baru (AKB) atau normal baru di objek wisata Pangandaran, sehingga bisa ...
Large caps deny they're being outgunned by smaller peers in health R&D - Stockhead
09:18am, Wednesday, 10'th Jun 2020
The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a d
Filled jobs fall 0.1 per cent: Aus shares close 0.1% higher
07:08am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and M
What's Opthea eyeing now that it has two successful trials under its belt? - Stockhead
03:44am, Wednesday, 10'th Jun 2020
Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema
Opthea (ASX:OPT) reports positive trial results: Aus shares 0.5% higher at noon
02:49am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic M
Opthea's done it again: Its drug passed its DME clinical trial - Stockhead
12:16am, Wednesday, 10'th Jun 2020
Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient ph
Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19
08:44pm, Monday, 08'th Jun 2020
Aerpio Pharmaceuticals, Inc. (the “Company”) (ARPO), today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations a
Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma
01:00pm, Monday, 08'th Jun 2020
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced
New Strong Buy Stocks For June 5th
12:46pm, Friday, 05'th Jun 2020
New Strong Buy Stocks For June 5th
Gubernur Jabar uraikan lima tahap adaptasi normal baru
12:57pm, Tuesday, 02'nd Jun 2020
Gubernur Jawa Barat (Jabar) yang juga Ketua Gugus Tugas Percepatan Penanggulangan COVID-19 Jabar M Ridwan Kamil mengemukakan lima tahap adaptasi normal ...
Company News for May 29, 2020
01:59pm, Friday, 29'th May 2020
Companies In The News Are: ABIO, ARPO, LL, DLTR
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
11:22am, Friday, 29'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * A
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
12:00am, Friday, 29'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...